Comparing a new breast cancer drug to an approved one in healthy men
Part of Cancer, Skin clinical trials.
This study compares a new drug called QL1209 with an approved drug called Perjeta (pertuzumab) in healthy male volunteers. It checks how the body handles each drug and whether they work similarly. This is an early study, so it does not treat cancer but helps determine if the new drug is a good match for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man between 18 and 55 years old.
- You weigh at least 110 pounds (50 kg) and your body mass index (BMI) is between 18.5 and 32.
- You are generally healthy with no major medical conditions like heart, liver, kidney, or lung problems.
- Your heart function (measured by an echocardiogram) and your kidney function are within normal ranges.
- You agree to use reliable birth control and not donate sperm during the study and for 7 months after the drug infusion.
- You have not taken any prescription, over-the-counter, herbal, or nutritional supplements within the last 14 days, and no other investigational drugs within the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, QL1706, given alongside chemotherapy before surgery for a certain type of breast cancer. It aims to see if this combination helps shrink tumors before they are removed.
This trial compares two combinations of drugs given before surgery to shrink HER2-positive breast cancer. One uses a new experimental drug (TQB2102) and the other uses standard treatments. The goal is to see which works better at reducing the cancer before surgery.
This trial tests a new medicine called TQB2102 against the standard combination of chemotherapy (docetaxel) plus two targeted therapies (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. The goal is to see if the new treatment works better and has fewer side effects.
This study tests a new drug called TQB3126 for people with breast cancer that has gotten worse after previous treatments. The goal is to see if the drug is safe and helps shrink or slow the cancer.
This study compares a new experimental drug called QL2109 with an approved treatment called daratumumab in healthy male volunteers. It is a first-in-human trial, which means the drug is being tested in people for the first time.
This trial tests a new immunotherapy drug (QL1706) combined with a short course of common chemotherapy (anthracyclines or taxanes) for people with early-stage triple-negative breast cancer. The goal is to see if this combination is safe and helps shrink the tumor before surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.